| Priming Immunotherapy in Advanced Disease With Radiation (NCT03313804) | John L. Villano, MD, PhD | 2017-10-26 |
| Safety and Efficacy of Xalkori ROS1 (NCT03375242) | Pfizer | 2017-10-25 |
| Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients (NCT03137264) | AstraZeneca | 2017-10-24 |
| Adjuvant CCRT vs CT in Minimal N2 NSCLC (NCT01066234) | Samsung Medical Center | 2017-10-23 |
| Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing (NCT03320044) | Peking University People's Hospital | 2017-10-18 |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (NCT03307785) | Tesaro, Inc. | 2017-10-12 |
| Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance (NCT03267654) | Qilu Pharmaceutical Co., Ltd. | 2017-10-12 |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer (NCT03215810) | H. Lee Moffitt Cancer Center and Research Institute | 2017-10-11 |
| Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer (NCT03217071) | Sue Yom | 2017-10-04 |
| Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents (NCT03242915) | University of Michigan Rogel Cancer Center | 2017-10-03 |
| ENB Robotic ICG Guided Surgery: A Novel Technique for Targeting Small Lung Tumors (NCT02570958) | St. Joseph's Healthcare Hamilton | 2017-10-01 |
| Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer (NCT04425681) | Second Affiliated Hospital of Nanchang University | 2017-10-01 |
| IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer (NCT03258671) | LuBing | 2017-10-01 |
| X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (NCT03215693) | Betta Pharmaceuticals Co., Ltd. | 2017-09-28 |
| Pembrolizumab + Idelalisib for Lung Cancer Study (NCT03257722) | Asha Nayak | 2017-09-26 |
| Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (NCT03177291) | H. Lee Moffitt Cancer Center and Research Institute | 2017-09-26 |
| Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) (NCT02920450) | University of Florida | 2017-09-25 |
| A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT03178552) | Hoffmann-La Roche | 2017-09-22 |
| A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (NCT03267316) | Cantargia AB | 2017-09-19 |
| Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) (NCT03285321) | Greg Durm, MD | 2017-09-15 |
| Study of High Efficient Killing Cell Therapy for Advanced NSCLC (NCT03193567) | Ruijin Hospital | 2017-09-14 |
| A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC (NCT03202940) | Massachusetts General Hospital | 2017-09-14 |
| Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer (NCT03198923) | Wenxiang Wang | 2017-09-13 |
| A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (NCT03191786) | Hoffmann-La Roche | 2017-09-11 |
| Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (NCT03087448) | University of California, San Francisco | 2017-09-09 |
| Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting. (NCT03219970) | AstraZeneca | 2017-09-05 |
| Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (NCT03170960) | Exelixis | 2017-09-05 |
| A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC (NCT03150875) | Innovent Biologics (Suzhou) Co. Ltd. | 2017-09-01 |
| Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer (NCT03481114) | Albert Einstein College of Medicine | 2017-08-28 |
| Cell Free DNA for the Diagnosis and Treatment in Early NSCLC (NCT03791034) | Samsung Medical Center | 2017-08-28 |
| A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (NCT03215706) | Bristol-Myers Squibb | 2017-08-24 |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers (NCT03190174) | Sarcoma Oncology Research Center, LLC | 2017-08-24 |
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms (NCT03219268) | MacroGenics | 2017-08-18 |
| Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors (NCT03392233) | RenJi Hospital | 2017-08-18 |
| BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer (NCT03386955) | Beta Pharma Shanghai | 2017-08-16 |
| mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer (NCT03196986) | Beijing Mabworks Biotech Co., Ltd. | 2017-08-15 |
| Pembrolizumab + CVA21 in Advanced NSCLC (NCT02824965) | Olivia Newton-John Cancer Research Institute | 2017-08-09 |
| the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) (NCT03264794) | Jiangsu Famous Medical Technology Co., Ltd. | 2017-08-01 |
| MRI Adaptive Replanning Using ViewRay (NCT02950792) | University of Miami | 2017-08-01 |
| Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT03245177) | Prof Corinne Faivre-Finn | 2017-08-01 |
| Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA (NCT03228277) | Konkuk University Medical Center | 2017-07-17 |
| Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 (NCT03003468) | Lawrence Feldman, MD | 2017-07-11 |
| Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT02730247) | Liza Villaruz, MD | 2017-07-05 |
| Resistance to Oral Therapy in Lung Cancer (NCT04546282) | University Hospital, Montpellier | 2017-07-01 |
| Concordance of Inivata Liquid Biopsy With Standard Tissue Biopsy (NCT03116633) | Inivata | 2017-06-30 |
| Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC (NCT03201146) | West China Hospital | 2017-06-27 |
| Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) (NCT03117049) | Ono Pharmaceutical Co., Ltd. | 2017-06-13 |
| Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors (NCT03138889) | Nektar Therapeutics | 2017-06-09 |
| Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial (NCT02664181) | Case Comprehensive Cancer Center | 2017-06-06 |
| Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (NCT03090737) | Bristol-Myers Squibb | 2017-06-02 |
| PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors (NCT03149549) | CytomX Therapeutics | 2017-06-01 |
| Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors (NCT02538432) | University of Maryland, Baltimore | 2017-06-01 |
| Modifying Your Diet to Support Muscle During Cancer Treatment. (NCT03010657) | University of Alberta | 2017-06-01 |
| Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient (NCT03132493) | Spanish Lung Cancer Group | 2017-06-01 |
| PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients (NCT03064854) | Novartis Pharmaceuticals | 2017-05-24 |
| Explore Intra-tumor Heterogeneity and Prognostic Value of Postoperative Blood ctDNA of ⅡA - ⅢA Stage Non-squamous NSCLC Based on the Capture-based Sequencing and UMI Technology of Burning Rock (NCT03337711) | Sun Yat-sen University | 2017-05-24 |
| Microbiota and the Lung Cancer (NCT03068663) | Centre Jean Perrin | 2017-05-23 |
| Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression (NCT03125200) | ADC Therapeutics S.A. | 2017-05-18 |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922) | USWM CT, LLC | 2017-05-15 |
| Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours (NCT03101839) | AstraZeneca | 2017-05-15 |
| Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (NCT02314481) | University College, London | 2017-05-12 |
| Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC (NCT03141359) | Wake Forest University Health Sciences | 2017-05-12 |
| Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer (NCT02898116) | Ludwig Institute for Cancer Research | 2017-05-10 |
| Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer (NCT03122717) | Dana-Farber Cancer Institute | 2017-05-09 |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (NCT03157128) | Eli Lilly and Company | 2017-05-02 |
| Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect (NCT03825510) | Crozer-Keystone Health System | 2017-04-28 |
| Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC) (NCT03198117) | Qidong Gaitianli Medicines Co., Ltd | 2017-04-25 |
| Clinical Trial in Chinese Healthy Volunteers of GB222 (NCT04175158) | Genor Biopharma Co., Ltd. | 2017-04-24 |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study (NCT03875092) | Merck Sharp & Dohme LLC | 2017-04-21 |
| A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3) (NCT02927301) | Genentech, Inc. | 2017-04-20 |
| Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala (NCT03209128) | Centre Francois Baclesse, Luxembourg | 2017-04-20 |
| Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients (NCT03081689) | Spanish Lung Cancer Group | 2017-04-15 |
| Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer (NCT03091491) | National Cancer Centre, Singapore | 2017-04-07 |
| Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies (NCT03607149) | Centre Georges Francois Leclerc | 2017-04-06 |
| International Lung Screen Trial (ILST) (NCT02871856) | The University of Queensland | 2017-04-05 |
| Detection of Circulating Biomarkers of Immunogenic Cell Death (NCT02921854) | Maastricht Radiation Oncology | 2017-04-04 |
| β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC (NCT03123484) | China Medical University, China | 2017-04-01 |
| A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan (NCT03273790) | Bristol-Myers Squibb | 2017-04-01 |
| Endostar First-line Treatment of Advanced NSCLC (NCT03123445) | China Medical University, China | 2017-04-01 |
| An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (NCT03001882) | Bristol-Myers Squibb | 2017-03-29 |
| Phase II Trial of Continuation Therapy in Advanced NSCLC (NCT03083808) | Greg Durm, MD | 2017-03-20 |
| Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors (NCT02706626) | Criterium, Inc. | 2017-03-09 |
| Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients (NCT02879760) | Turnstone Biologics, Corp. | 2017-03-08 |
| A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (NCT02998528) | Bristol-Myers Squibb | 2017-03-04 |
| Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC (NCT02908750) | AstraZeneca | 2017-03-02 |
| Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC (NCT03130764) | Columbia University | 2017-03-01 |
| The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients (NCT03228368) | First Affiliated Hospital of Zhejiang University | 2017-03-01 |
| Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor (NCT03093688) | Shanghai Public Health Clinical Center | 2017-03-01 |
| Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC (NCT02929290) | Betta Pharmaceuticals Co., Ltd. | 2017-03-01 |
| Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients (NCT02758314) | Instituto Nacional de Cancerologia de Mexico | 2017-03-01 |
| To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer (NCT03195569) | Qilu Pharmaceutical Co., Ltd. | 2017-03-01 |
| Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy (NCT03017885) | Boehringer Ingelheim | 2017-02-28 |
| Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC (NCT03074864) | Guangdong Provincial People's Hospital | 2017-02-27 |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma (NCT02974725) | Novartis Pharmaceuticals | 2017-02-24 |
| A Study Evaluating MM-310 in Patients With Solid Tumors (NCT03076372) | Merrimack Pharmaceuticals | 2017-02-22 |
| Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC (NCT03614065) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2017-02-21 |
| Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study (NCT02803333) | H. Lee Moffitt Cancer Center and Research Institute | 2017-02-16 |
| ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI) (NCT05221372) | Erasmus Medical Center | 2017-02-02 |
| AVID100 in Advanced Epithelial Carcinomas (NCT03094169) | Formation Biologics | 2017-02-01 |
| Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer (NCT03724500) | Chang Gung Memorial Hospital | 2017-02-01 |